OSI eyes third party options after board rejects Astellas bid
This article was originally published in Scrip
Executive Summary
OSI Pharmaceuticals' board has unanimously rejected Astellas's unsolicited $52 per share cash offer for the company, recommending that OSI shareholders do the same.